SVA [SINOVAC BIOTECH] 6-K: Sinovac Raises $86.73 Million Through Private Placement Transaction

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2018-07-03
Original SEC Filing: Click here


Webplus: SVA/20180703/6-K/2_EX-99.1/000.htm SEC Original: tv497880_ex99-1.htm
Sinovac Raises $86.73 Million Through Private Placement Transaction · Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac After the Private Placement Transaction · Proceeds Will Be Used to Fund Improvement and Construction of Facilities for R&D Relating to Quality Control and Production of New Vaccines Projects · Sinovac’s Board of Directors Terminates the Amalgamation Agreement




Webplus: SVA/20180703/6-K/3_EX-99.2/000.htm SEC Original: tv497880_ex99-2.htm
EXECUTION VERSION SECURITIES PURCHASE AGREEMENT by and among Vivo Capital, LLC, Prime Success, L.P., and Sinovac Biotech Ltd. , 2018 Dated as of July 2 TABLE OF CONTENTS Page Article 1 definitions 2 1.1 Definitions 2 1.2 Terms Defined Elsewhere 8 1.3 Other Definitional and Interpretative Provisions 10 Article 2 Purchase and Sale of Stock; closing 10 2.1 Issuance, Sale




Webplus: SVA/20180703/6-K/4_EX-99.3/000.htm SEC Original: tv497880_ex99-3.htm
EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT Agreement Company Investor Investors Shareholder Shareholders This REGISTRATION RIGHTS AGREEMENT (this “ Securities Purchase Agreement WHEREAS, the Company and the Investors are parties to the Securities Purchase Agreement, dated as of the date hereof (as the same may be amended, supplemented or otherwise modified from time to time, the “ WHEREAS, the Investors desire to




Webplus: SVA/20180703/6-K/5_EX-99.4/000.htm SEC Original: tv497880_ex99-4.htm
EXECUTION VERSION SINOVAC BIOTECH LTD. SHAREHOLDERS AGREEMENT Dated as of July 2, 2018 TABLE OF CONTENTS Page Article I INTRODUCTORY MATTERS 1 1.1 Defined Terms 1 1.2 Construction 8 Article II CORPORATE GOVERNANCE MATTERS 9 2.1 Composition of the Board 9 2.2 Qualification of the Investor Designee 10 2.3 Resignations 11 2.4 Co-Investor Observer 12 Article III VOTING MATTERS 12




Webplus: SVA/20180703/6-K/6_EX-99.5/000.htm SEC Original: tv497880_ex99-5.htm
EXECUTION VERSION PROMISSORY NOTE $43,365,000 July 2, 2018 FOR Payor Sinovac Biotech Ltd. Payee principal amount Principal Amount Note Purchase Agreement Payment of Principal and Interest 1. Interest Interest Rate 1.1 Payment Section 1.3 Outstanding Balance Maturity Date 1.2 Prepayment Payor prior to the Maturity Date Outstanding Balance upon prior written notice to Payee 1.3 Remedies on Default Event of




Webplus: SVA/20180703/6-K/7_EX-99.6/000.htm SEC Original: tv497880_ex99-6.htm
EXECUTION VERSION PROMISSORY NOTE $43,365,000 July 2, 2018 FOR Payor Sinovac Biotech Ltd. Payee principal amount Principal Amount Note Purchase Agreement Payment of Principal 1. Payment Section 1.2 Outstanding Balance Maturity Date 1.1 Prepayment Payor prior to the Maturity Date Outstanding Balance upon prior written notice to Payee 1.2 Remedies on Default Event of Default Payee (a) Outstanding Balance be




Webplus: SVA/20180703/6-K/8_EX-99.7/000.htm SEC Original: tv497880_ex99-7.htm
EXECUTION VERSION Advantech Master Investment Limited c/o Advantech Capital Suites 1702-03, 17/F One Exchange Square, 8 Connaught Place Central, Hong Kong July 2, 2018 Prime Success, L.P. c/o Advantech Capital Suites 1702-03, 17/F One Exchange Square, 8 Connaught Place Central, Hong Kong Sinovac Biotech Ltd. No. 39 Shangdi Xi Road Haidian District, Beijing 100085, China Re: Equity Commitment Letter and




Webplus: SVA/20180703/6-K/9_EX-99.8/000.htm SEC Original: tv497880_ex99-8.htm
Form of Director Confidentiality Agreement · July [ Director Company In connection with my nomination and service as a member of the board of directors (a “ Confidential Information 1. In connection with my service as a Director, I may acquire certain confidential, proprietary or competitively sensitive information that relates to the Company or its subsidiaries, and/or their respective directors,




Webplus: SVA/20180703/6-K/10_EX-99.9/000.htm SEC Original: tv497880_ex99-9.htm
Execution Version SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent Fourth TO RIGHTS AGREEMENT Effective as of July 2, 2018 Amendment Rights Agreement Company Rights Agent Securities Purchase Agreement This Fourth Amendment (this “ Amalgamation Agreement Parent Special Committee Board WHEREAS, the Special Committee (the “ WHEREAS, the Company and the Rights Agent have previously executed and




Webplus: SVA/20180703/6-K/1/000.htm SEC Original: tv497880_6k.htm



Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2018-07-03CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 15 ZHI TONG ROAD,, ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
BEIJING 102200

Home Page Forums

By | 2018-07-04T03:48:53+00:00 July 3rd, 2018|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar